Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes

Leukemia

Volumn 13, Issue 9, 1999, Pages 1441-1447

  Harada, S ^b   Suzuki, R ^b   Uehira, K ^b   Yatabe, Y ^b   Kagami, Y ^b   Ogura, M ^b   Suzuki, H ^b   Oyama, A ^b   Kodera, Y ^b   Ueda, R ^b   Morishima, Y ^b   Nakamura, S ^b   Seto, M ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

BCL2; BCL6; CD10; CD5; Diffuse large B cell lymphoma

Indexed keywords

CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; FEMALE; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032846422     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401487     Document Type: Article

References (38)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles TM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Lennert K, Feller AC. Histopathology of Non-Hodgkin-Lymphomas (based on the updated Kiel classification), 2nd edn. Springer: New York, 1992.
3. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
4. Izumo T, Uehara T, Kishi K, Maseki N, Mori S. Malignant lymphoma in Japanese HTLV1-nonendemic area, based on the REAL classification. Ann Oncol 1996; 7: 94 (Abstr.).
5. Magrath IT. The non-Hodgkin's Lymphomas: an introduction. The Non-Hodgkin's Lymphomas. Edward Arnold: London, 1990, p 1.
6. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosome translocation in malignant lymphomas. New Engl J Med 1987; 317: 1185-1189.
7. Osada H, Seto M, Ueda R, Emi N, Takagi N, Obata Y, Suchi T, Takahashi T. BCL2 gene rearrangement analysis in Japanese B cell lymphoma; novel BCL2 recombination with immunoglobulin K chain gene. Jpn J Cancer Res 1989; 80: 711-715.
8. Amakawa R, Fukuhara S, Ohno H, Doi S, Oguma S, Tanabe S, Yamabe H, Edamura S, Tomono N, Nasu K. Involvement of bcl-2 gene in Japanese follicular lymphoma. Blood 1989; 83: 787-791.
9. Banno S, Yoshikawa K, Nakamura S, Yamamoto K, Seito T, Nitta M, Takahashi T, Ueda R, Seto M. Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. Jpn J Cancer Res 1994; 85: 918-926.
10. Nakamura S, Seto M, Banno S, Suzuki S, Koshikawa T, Kitoh K, Kagami Y, Ogura M, Yatabe Y, Kojima M, Motoori T, Takahashi T, Ueda R, Suchi T. Immunohistochemical analysis on the cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. Jpn J Cancer Res 1994; 85: 1270-1279.
11. Kuroda H, Komatsu H, Nakamura S, Niitsu Y, Takahashi T, Ueda R, Seto M. The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Jpn J Cancer Res 1995; 86: 890-898.
12. Yatabe Y, Nakamura S, Seto M, Kuroda H, Kagami Y, Suzuki R, Ogura M, Kojima M, Koshikawa T, Ueda R, Suchi T. Clinicopathological study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 1996; 20: 1110-1122.
13. Offit K, Koduru PRK, Hollis R, Filippa D, Jhanwar SC, Clarkson BC, Chaganti RSK. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol 1989; 72: 178-183.
14. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2 MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol 1994; 12: 149-154.
15. Baron BW, Nucifora C, McCabe N, Espinosa R III, LeBeau MM, McKeithan TW. Identification of the gene associated with the recurring chromosomal translocation t(3;14) (q27;q11) in B-cell lymphomas. Proc Natl Acad Sci USA 1993; 90: 5262-5266.
16. Kerchaert JP, Deweindt C, Tilly H, Quief S, Lecocq C, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocation in human lymphomas. Nat Genet 1993; 5: 66-70.
17. Ye BH, Lista F, Knowles DM, Offit K, Chaganti RSK, Dalla-Favera R. Alterations of a zink finger-encoding gene, BCL6, in diffuse large-cell lymphoma. Science 1993; 262: 747-750.
18. Miki T, Kawamata N, Hirosawa S, Aoki N. Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL-5, encodes a Kruppel-like zinc-finger protein. Blood 1994; 83: 26-32.
19. Offit K, Lo Coco F, Louie DC, Parza NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyil M, Jhanwar S, Dalla-Favera R, Chaganti RSK. Rearrangement of the BCL6 gene as a prognostic marker in diffuse large-cell lymphoma. New Engl J Med 1994; 331: 74-80.
20. Bastard C, Deweindt C, Kerckaert JP, Lenormand B, Bossi A, Pezzella F, Fruchart C, Dubal C, Monconduit M, Tilly H. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423-2427.
21. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, Chaganti RSK, Dalla-Favera R. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83: 1757-1759.
22. Butler M, Corbally N, Dervan PA, Carney DN. BCL6 and other genomic alterations in non-Hodgkin's lymphoma (NHL). Br J Cancer 1997; 75: 1641-1645.
23. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-1493.
24. Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, Ichimaru M, Ogawa M, Kimura I, Tominaga S, Tsugane S, Taguchi H, Minato K, Takenaka T, Tobinai K, Kurita S, Oyama A, Hisano S, Kozuru M, Matsumoto M, Nomura K, Takiguchi T, Sugai S, Yamaguchi K, Hattori T, Kinoshita K, Tajima K, Suematsu K for the Lymphoma Study Group. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988; 6: 128-141.
25. Seto M, Yamamoto K, Iida S, Akao Y, Utsumi KR, Kubonishi I, Miyoshi I, Ohtsuki T, Yawata Y, Namba M, Motokura T, Arnold A, Takahashi T, Ueda R. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t (11;14) (q13;q32) translocation. Oncogene 1992; 7: 1401-1406.
26. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Mantel N. Evaluation of survival data two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
28. Dalla-Favera R, Ye BH, Cattoretti G, Lo Coco F, Chang C, Zhang J, Migliazza A, Cechova K, Niu H, Chaganti S, Chen W, Louie DC, Offit K, Chaganti RSK. BCL6 in diffuse large-cell lymphomas. In: DeVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology 1996. Lippincott-Raven: Philadelphia, PA, 1996, pp 139-148.
29. Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, Calvi R, Freilone R, Novero D, Orsucci L, Pastore C, Capello D, Parvis G, Sacco C, Zagonel V, Carbone A, Mazza U, Parestro G, Saglio G, Resegotti L. Rearrangements of bcl-6, bc1-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998; 9: 55-61.
30. H segment of immunogloblin genes of CD5 positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997; 88: 1087-1093.
31. H genes with somatic mutation. Blood 1998; 91: 1145-1151.
32. Liu YJ, Johnson GD, Gordon J, MacLennan ICM. Germinal centers in T-cell-dependent antibody responses. Immunol Today 1992; 13: 17-21.
33. Lebecque S, Bouteiller O, Arpin C, Banchereau J, Liu YJ. Germinal center founder cells display propensity for apoptosis before onset of somatic mutation. J Exp Med 1997; 185: 563-571.
34. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90: 1168-1174.
35. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F, Gaulard P for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265-272.
36. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
37. Ye BH, Catoretti G, Shen Q, Zhang J, Hawe N, Waard R, Leung C, Nouri-Shirazi M, Orazi A, Chaganti RSK, Rothman P, Stall AM, Pandolfi PP, Dalla-Favera R. The BCL6 proto-oncogene controls germinal-center formation and Th2-type inflammation. Nat Genet 1997; 16: 161-170.
38. Cattoretti G, Chang C, Cechova K, Zhang J, Ye BH, Falini B, Louie DC, Offit K, Chaganti RSK, Dalla-Favera R. BCL-6 protein is expressed in germinal center B cells. Blood 1995; 86: 45-53.